Inspire Biotherapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Inspire Biotherapeutics's estimated annual revenue is currently $387.5k per year.
- Inspire Biotherapeutics's estimated revenue per employee is $77,500
Employee Data
- Inspire Biotherapeutics has 5 Employees.
- Inspire Biotherapeutics grew their employee count by 0% last year.
Inspire Biotherapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO & COO | Reveal Email/Phone |
2 | Chief Business Officer (Interim) | Reveal Email/Phone |
Inspire Biotherapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is Inspire Biotherapeutics?
Inspire has developed a lung tropic AAV gene therapy platform that has demonstrated transduction and long-term expression in lung tissue without impact on other tissue types in disease-relevant animal models. We are currently pursing initiation of a Proof-of-Concept clinical trial for a lethal neonatal lung disease with short time to data readout and success of therapy. The platform can then be applied to Cystic Fibrosis and other monogenic lung diseases.
keywords:N/A
N/A
Total Funding
5
Number of Employees
$387.5k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.1M | 5 | -29% | $36M |
#2 | $0.6M | 5 | -29% | N/A |
#3 | $0.1M | 5 | -29% | $12M |
#4 | $0.5M | 5 | -17% | $76.7M |
#5 | $0.4M | 5 | 0% | N/A |